Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Skin Neoplasms 1 Radiodermatitis 1 Neoplasms, Squamous Cell 1 Melanoma 1 Immune System Diseases 1 Carcinoma, Squamous Cell 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 14 fludarabine 9 fludarabine phosphate 8 Busulfan 5 Bendamustine Hydrochloride 5 Tacrolimus 4 Rituximab 4 Mycophenolic Acid 4 ibrutinib 3 Melphalan 3 Bortezomib 3 AP 1903 reagent 3 tetulomab tetraxetan lu-177 2 ponatinib 2 pembrolizumab 2 cobomarsen 2 Whole-Body Irradiation 2 Vorinostat 2 Vincristine 2 Prednisone 2 Peripheral Blood Stem Cell Transplantation 2 Patient Reported Outcome Measures 2 Mesna 2 Lutetium 2 Etoposide 2 Doxorubicin 2 Brentuximab Vedotin 2 Bone Marrow Transplantation 2 thymoglobulin 1 pimonidazole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Immune System Diseases × Dimethyl Sulfoxide × Clear all

NCT02519816 2019-08-14

CARE

Maisonneuve-Rosemont Hospital

Phase 2 Unknown

Immune System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡